Keros Therapeutics Inc (KROS) 13F Investor Activity Report (Q2 2026)

KROS ranks #3963 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

KROS is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

133 institutions disclose a position in KROS, but none treat it as a major bet — even Nantahala Capital Management, LLC, its most concentrated holder, allocates just 0.5% of its own portfolio to it.

Cliff Asness has added to its KROS position for two straight quarters, increasing it by $6.7M to reach $10.4M today.

Arrowstreet Capital, Limited Partnership has trimmed its KROS position for two straight quarters, cutting it by $24.7M while still holding $2.5M.

KROS is down 4.8% today, but institutions show net buying of $3.3M this quarter — a divergence between today's price move and the underlying institutional flow.

KROS reported a net loss of $83.2M over the trailing twelve months.

• Not yet profitable — net loss of $83.2M over the trailing twelve months
• Revenue declined 93.6% year over year
• Net income declined year over year, from $18.8M to -$83.2M
• Generated $107.5M in positive operating cash flow
• Current ratio of 15.45x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.12x equity — within a conventional range